United States: OIG Reports On, Proposes Alternatives To Medicare Part B Reimbursement For 340B Drugs

In November 2015, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) published a report (the Report) on the subject of Medicare Part B (Part B) payments made for covered outpatient drugs purchased through the 340B Drug Pricing Program (340B Program). The Report is the result of an OIG review, through which OIG sought to determine the extent to which Part B payments to hospitals and other entities participating in the 340B Program (Covered Entities) for covered outpatient drugs exceeded the cost to such Covered Entities in acquiring those drugs. In sum, OIG found that in 2013, Part B payments exceeded drug costs to Covered Entities by approximately $1.3 billion. OIG notes that the Report, which also sets forth three potential mechanisms whereby Part B could share in that excess payment amount, is intended to be used by stakeholders in future discussions on the distribution of 340B Program savings and the reduction in overall Medicare spending.   

The 340B Program allows Covered Entities to purchase covered outpatient drugs from manufacturers at discounted prices. The Health Resources and Services Administration (HRSA) sets the maximum price that a manufacturer can charge for a 340B-eligible drug, which is calculated each quarter (also known as the Ceiling Price). Covered Entities dispense 340B drugs to eligible patients, and are reimbursed for the dispensed drugs by applicable third party payors. 

Covered Entities may provide 340B drugs to Part B patients. Part B pays for most covered outpatient drugs on the basis of volume-weighted average sales prices (ASPs). According to the Report, in 2013, Medicare Part B paid for most covered outpatient drugs at 106 percent of ASP.  Part B beneficiaries are responsible for 20 percent of all Part B payments, including payments for drugs. 

In producing the Report, OIG reviewed claims submitted by Covered Entities to Part B for 340B-eligible drugs in 2013. OIG used this data to determine the differential between the 2013 Ceiling Prices for 340B-eligible drugs and the amounts actually paid by Part B (including Part B beneficiaries) to Covered Entities for such drugs. As noted briefly above, the Report states that the total payments by Part B and Part B beneficiaries to Covered Entities for 340B-eligible drugs in 2013 exceeded the Ceiling Prices for such drugs by $1.3 billion.

Currently, where a Covered Entity dispenses a 340B drug to a Part B beneficiary, the Covered Entity retains the entire differential between the cost of acquiring the 340B drug (often, the Ceiling Price) and the total payment received from Part B for such drug. The 340B Program does not mandate how a Covered Entity uses the savings generated by dispensing 340B drugs, including any savings generated by dispensing 340B drugs to Part B beneficiaries.

In the Report, OIG sets out three potential alternative payment methodologies whereby Part B and Part B beneficiaries could share in the savings accrued to Covered Entities through the 340B Program. The chart below sets forth the proposals as outlined in the Report, and illustrates the distribution of the savings generated which would have been generated by the 340B Program for 2013 for Covered Entities and for Part B under each methodology. 


Amount saved by Part B (2013)

Amount retained by Covered Entities (2013)

100% of ASP

$162 million

$1.11 billion

Equally shared savings (in 2013, this would have been ASP minus 14.4%)

$638 million

$638 million

Ceiling Price plus 6% of ASP

$1.06 billion

$211 million


In each scenario, Part B would reduce reimbursement to Covered Entities for 340B-eligible drugs dispensed to Part B beneficiaries. As illustrated above, the three alternative payment methodologies vary in how the savings would be shared between Part B and the Covered Entities. Relatedly, the total savings to the Part B Program varies among the three options: the first alternative methodology (100 percent of ASP) represents a 5 percent reduction in total Part B expenditures on 340B drugs, the second methodology represents an 18 percent reduction and the third represents a 31 percent reduction in Part B spending on 340B drugs.

The Report is careful to note that the financial analysis contained therein does not take into account the potential effects on those communities served by Covered Entities. From the Covered Entity perspective, the proposed shared-savings mechanisms may make the 340B Program less viable, and Covered Entities may be discouraged from participation. The proposals contained in the Report may also cause additional administrative burdens on Covered Entities, because such proposals would require a Covered Entity to specifically identify 340B drugs on Medicare Part B claims (e.g., through the use of a modifier).

As noted by OIG, the Report is intended to serve as a tool for future discussions pertaining to the 340B Program, the use of savings by Covered Entities and the reduction in overall Part B payments. It appears that the Centers for Medicare & Medicaid Services (CMS) would be unable to implement any change to the payment methodology, including adoption of any of the proposed methods mentioned in the Report, absent regulatory (or potentially, statutory) action.  In light of this Report, it is possible that public and private stakeholders alike will engage in discussions about redistributing at least some of the savings which are generated by the 340B Program. 

OIG Reports on, Proposes Alternatives to Medicare Part B Reimbursement for 340B Drugs

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.